All In Biotech

Free tool

FAERS Monitor: Truqap

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218197 or its brand name (Truqap, Capivasertib). Reports on generic versions are filed under their own applications.

Reports

3,065

Serious

2,565

84% of reports

Hospitalization

888

Death reported

590

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death465
  • diarrhoea455
  • rash400
  • hyperglycaemia356
  • malignant neoplasm progression175
  • nausea164
  • vomiting132
  • fatigue129
  • blood glucose increased128
  • disease progression118
  • diabetic ketoacidosis93
  • pyrexia93
  • erythema multiforme82
  • decreased appetite81
  • product dose omission issue79

Reports by year received

View as table
YearReports
20141
20161
20206
20212
20223
20235
2024827
20251,229
2026991

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,094 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperglycaemiaSignal35667.761.423,139
erythema multiformeSignal8260.949.14,728
diabetic ketoacidosisSignal9326.721.82,266
malignant neoplasm progressionSignal17511.710.21,715
disease progressionSignal1186.85.7586
rashSignal4006.35.81,815
diarrhoeaSignal4554.84.41,425
blood glucose increasedSignal1284.73.9368
deathSignal4653.73.4954
decreased appetiteSignal812.41.965
vomiting1321.91.659
pyrexia931.81.536
product dose omission issue791.81.530
nausea1641.41.221
fatigue1291.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.